AR085711A1 - Compuesto de heteroaril oximetilen arilo sustituido, composicion farmaceutica y combinacion que lo comprenden y su uso para la fabricacion de un medicamento para el tratamiento de una enfermedad autoinmune, cancer, una enfermedad inflamatoria y/o un trastorno alergico y una enfermedad asociada con la activacion inapropiada de las celulas cebadas - Google Patents
Compuesto de heteroaril oximetilen arilo sustituido, composicion farmaceutica y combinacion que lo comprenden y su uso para la fabricacion de un medicamento para el tratamiento de una enfermedad autoinmune, cancer, una enfermedad inflamatoria y/o un trastorno alergico y una enfermedad asociada con la activacion inapropiada de las celulas cebadasInfo
- Publication number
- AR085711A1 AR085711A1 ARP120100750A ARP120100750A AR085711A1 AR 085711 A1 AR085711 A1 AR 085711A1 AR P120100750 A ARP120100750 A AR P120100750A AR P120100750 A ARP120100750 A AR P120100750A AR 085711 A1 AR085711 A1 AR 085711A1
- Authority
- AR
- Argentina
- Prior art keywords
- hydrogen
- alkyl
- cancer
- manufacture
- pharmaceutical composition
- Prior art date
Links
- 208000023275 Autoimmune disease Diseases 0.000 title abstract 2
- 206010028980 Neoplasm Diseases 0.000 title abstract 2
- 201000011510 cancer Diseases 0.000 title abstract 2
- 208000027866 inflammatory disease Diseases 0.000 title abstract 2
- 238000004519 manufacturing process Methods 0.000 title abstract 2
- 239000008194 pharmaceutical composition Substances 0.000 title abstract 2
- 230000006978 adaptation Effects 0.000 title 1
- 239000002131 composite material Substances 0.000 title 1
- 229940126601 medicinal product Drugs 0.000 title 1
- 229910052739 hydrogen Inorganic materials 0.000 abstract 5
- 239000001257 hydrogen Substances 0.000 abstract 5
- 125000004435 hydrogen atom Chemical group [H]* 0.000 abstract 5
- 125000004169 (C1-C6) alkyl group Chemical group 0.000 abstract 4
- 150000003839 salts Chemical class 0.000 abstract 4
- 125000004191 (C1-C6) alkoxy group Chemical group 0.000 abstract 3
- 150000001875 compounds Chemical class 0.000 abstract 3
- 208000037265 diseases, disorders, signs and symptoms Diseases 0.000 abstract 2
- 230000004913 activation Effects 0.000 abstract 1
- 239000013543 active substance Substances 0.000 abstract 1
- 125000000217 alkyl group Chemical group 0.000 abstract 1
- 230000000172 allergic effect Effects 0.000 abstract 1
- 208000010668 atopic eczema Diseases 0.000 abstract 1
- 208000030949 chronic idiopathic urticaria Diseases 0.000 abstract 1
- 206010072757 chronic spontaneous urticaria Diseases 0.000 abstract 1
- 208000024376 chronic urticaria Diseases 0.000 abstract 1
- 239000003085 diluting agent Substances 0.000 abstract 1
- 201000010099 disease Diseases 0.000 abstract 1
- 208000035475 disorder Diseases 0.000 abstract 1
- 239000003814 drug Substances 0.000 abstract 1
- 239000003937 drug carrier Substances 0.000 abstract 1
- ZZUFCTLCJUWOSV-UHFFFAOYSA-N furosemide Chemical compound C1=C(Cl)C(S(=O)(=O)N)=CC(C(O)=O)=C1NCC1=CC=CO1 ZZUFCTLCJUWOSV-UHFFFAOYSA-N 0.000 abstract 1
- 125000001475 halogen functional group Chemical group 0.000 abstract 1
- -1 heteroaryl oxymethylene aryl compound Chemical class 0.000 abstract 1
- 206010025135 lupus erythematosus Diseases 0.000 abstract 1
- 239000000546 pharmaceutical excipient Substances 0.000 abstract 1
Classifications
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D403/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00
- C07D403/02—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00 containing two hetero rings
- C07D403/12—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00 containing two hetero rings linked by a chain containing hetero atoms as chain links
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D401/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom
- C07D401/02—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings
- C07D401/12—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings linked by a chain containing hetero atoms as chain links
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D401/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom
- C07D401/14—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing three or more hetero rings
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
- A61K31/47—Quinolines; Isoquinolines
- A61K31/472—Non-condensed isoquinolines, e.g. papaverine
- A61K31/4725—Non-condensed isoquinolines, e.g. papaverine containing further heterocyclic rings
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/55—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having seven-membered rings, e.g. azelastine, pentylenetetrazole
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K45/00—Medicinal preparations containing active ingredients not provided for in groups A61K31/00 - A61K41/00
- A61K45/06—Mixtures of active ingredients without chemical characterisation, e.g. antiphlogistics and cardiaca
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/0012—Galenical forms characterised by the site of application
- A61K9/0014—Skin, i.e. galenical aspects of topical compositions
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P13/00—Drugs for disorders of the urinary system
- A61P13/12—Drugs for disorders of the urinary system of the kidneys
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P17/00—Drugs for dermatological disorders
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P17/00—Drugs for dermatological disorders
- A61P17/02—Drugs for dermatological disorders for treating wounds, ulcers, burns, scars, keloids, or the like
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P17/00—Drugs for dermatological disorders
- A61P17/04—Antipruritics
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P19/00—Drugs for skeletal disorders
- A61P19/02—Drugs for skeletal disorders for joint disorders, e.g. arthritis, arthrosis
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P19/00—Drugs for skeletal disorders
- A61P19/04—Drugs for skeletal disorders for non-specific disorders of the connective tissue
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P35/00—Antineoplastic agents
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P37/00—Drugs for immunological or allergic disorders
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P37/00—Drugs for immunological or allergic disorders
- A61P37/02—Immunomodulators
- A61P37/06—Immunosuppressants, e.g. drugs for graft rejection
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P37/00—Drugs for immunological or allergic disorders
- A61P37/08—Antiallergic agents
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P7/00—Drugs for disorders of the blood or the extracellular fluid
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P9/00—Drugs for disorders of the cardiovascular system
Landscapes
- Health & Medical Sciences (AREA)
- Chemical & Material Sciences (AREA)
- Organic Chemistry (AREA)
- Veterinary Medicine (AREA)
- Pharmacology & Pharmacy (AREA)
- Public Health (AREA)
- General Health & Medical Sciences (AREA)
- Animal Behavior & Ethology (AREA)
- Medicinal Chemistry (AREA)
- Life Sciences & Earth Sciences (AREA)
- General Chemical & Material Sciences (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Chemical Kinetics & Catalysis (AREA)
- Engineering & Computer Science (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Epidemiology (AREA)
- Immunology (AREA)
- Dermatology (AREA)
- Rheumatology (AREA)
- Physical Education & Sports Medicine (AREA)
- Pulmonology (AREA)
- Transplantation (AREA)
- Pain & Pain Management (AREA)
- Heart & Thoracic Surgery (AREA)
- Orthopedic Medicine & Surgery (AREA)
- Cardiology (AREA)
- Hematology (AREA)
- Urology & Nephrology (AREA)
- Biomedical Technology (AREA)
- Diabetes (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
- Plural Heterocyclic Compounds (AREA)
- Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
Abstract
Un compuesto de heteroaril oximetilén arilo sustituido de la fórmula (1) en la que: X es CR¹ o N; Y es CH, C o N; R¹ es hidrógeno, alcoxi C₁₋₆ o alquilo C₁₋₆; R² es hidrógeno, alcoxi C₁₋₆, halo, -C(O)alquilo C₁₋₆, CN, halo-alquilo C₁₋₆ o C(O)NR⁴R⁵; R³ es hidrógeno o alcoxi C₁₋₆; R⁴ es hidrógeno o alquilo C₁₋₆; R⁵ es hidrógeno o alquilo C₁₋₆; y m y n son números enteros seleccionado cada uno independientemente de 1 y 2; o una de sus sales. Una composición farmacéutica que comprende el compuesto de la fórmula (1) o una de las sales farmacéuticamente aceptables y uno o más vehículos, diluyentes o excipientes farmacéuticamente aceptables y una combinación que comprende dicho compuesto o una de sus sales farmacéuticamente aceptables junto con uno o más de otros agentes terapéuticamente activos. Uso del compuesto o una de sus sales farmacéuticamente aceptables para la fabricación de un medicamento para el tratamiento de una enfermedad autoinmune, tal como urticaria idiopática crónica con y sin auto-anticuerpos o lupus discoide (cutáneo); del cáncer; de una enfermedad inflamatoria y/o trastorno alérgico y de una enfermedad asociada con la activación inapropiada de las células cebadas.
Applications Claiming Priority (1)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| GBGB1104153.0A GB201104153D0 (en) | 2011-03-11 | 2011-03-11 | Novel compounds |
Publications (1)
| Publication Number | Publication Date |
|---|---|
| AR085711A1 true AR085711A1 (es) | 2013-10-23 |
Family
ID=43980841
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| ARP120100750A AR085711A1 (es) | 2011-03-11 | 2012-03-08 | Compuesto de heteroaril oximetilen arilo sustituido, composicion farmaceutica y combinacion que lo comprenden y su uso para la fabricacion de un medicamento para el tratamiento de una enfermedad autoinmune, cancer, una enfermedad inflamatoria y/o un trastorno alergico y una enfermedad asociada con la activacion inapropiada de las celulas cebadas |
Country Status (41)
Families Citing this family (8)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| WO2014081616A1 (en) * | 2012-11-21 | 2014-05-30 | Merck Sharp & Dohme Corp. | Preparation of precursors for leukotriene antagonists |
| JP2018521089A (ja) * | 2015-07-24 | 2018-08-02 | グラクソ グループ リミテッドＧｌａｘｏ Ｇｒｏｕｐ Ｌｉｍｉｔｅｄ | 白斑の治療 |
| SG11202002475TA (en) | 2017-10-19 | 2020-04-29 | Bayer Animal Health Gmbh | Use of fused heteroaromatic pyrrolidones for treatment and prevention of diseases in animals |
| CN114364798A (zh) | 2019-03-21 | 2022-04-15 | 欧恩科斯欧公司 | 用于治疗癌症的Dbait分子与激酶抑制剂的组合 |
| EP3958851B1 (en) * | 2019-04-23 | 2024-08-14 | The Cleveland Clinic Foundation | Allosteric activators of the alpha ia-adrenergic receptor |
| JP2023500906A (ja) | 2019-11-08 | 2023-01-11 | インサーム（インスティテュ ナシオナル ドゥ ラ サンテ エ ドゥ ラ ルシェルシェ メディカル） | キナーゼ阻害剤に対する獲得抵抗性を有するがんの処置方法 |
| WO2021148581A1 (en) | 2020-01-22 | 2021-07-29 | Onxeo | Novel dbait molecule and its use |
| CN113340965B (zh) * | 2020-03-03 | 2022-12-16 | 北京中医药大学 | 一种用于检测扑尔敏用途的人工智能生物传感器检测方法 |
Family Cites Families (102)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| JPS56138200A (en) | 1980-02-15 | 1981-10-28 | Glaxo Group Ltd | Androstane carbothioate compound |
| AU570439B2 (en) | 1983-03-28 | 1988-03-17 | Compression Labs, Inc. | A combined intraframe and interframe transform coding system |
| GB9004781D0 (en) | 1990-03-02 | 1990-04-25 | Glaxo Group Ltd | Device |
| FR2665159B1 (fr) | 1990-07-24 | 1992-11-13 | Rhone Poulenc Sante | Nouveaux derives de la pyridine et de la quinoleine, leur preparation et les compositions pharmaceutiques qui les contiennent. |
| GB9127376D0 (en) | 1991-12-24 | 1992-02-19 | Wellcome Found | Amidino derivatives |
| EP0633776B1 (en) | 1992-04-02 | 2001-05-09 | Smithkline Beecham Corporation | Compounds useful for treating allergic and inflammatory diseases |
| IL108630A0 (en) * | 1993-02-18 | 1994-05-30 | Fmc Corp | Insecticidal substituted 2,4-diaminoquinazolines |
| US5426196A (en) | 1993-12-22 | 1995-06-20 | Glaxo Inc. | Synthesis of diaryl methanes |
| DK0765308T3 (da) | 1994-06-15 | 2000-09-11 | Wellcome Found | Enzyminhibitorer |
| WO1997029079A1 (en) | 1996-02-06 | 1997-08-14 | Japan Tobacco Inc. | Novel compounds and pharmaceutical use thereof |
| MY117948A (en) | 1997-01-13 | 2004-08-30 | Glaxo Group Ltd | Nitride oxide synthase inhibitors. |
| PH11998001073B1 (en) | 1997-05-07 | 2007-07-23 | Univ Pittsburgh | Inhibitors of protein isoprenyl transferases |
| DE19723722A1 (de) | 1997-05-30 | 1998-12-10 | Schering Ag | Nichtsteroidale Gestagene |
| AU9281298A (en) | 1997-10-01 | 1999-04-23 | Kyowa Hakko Kogyo Co. Ltd. | Benzodioxole derivatives |
| AU9781098A (en) | 1997-10-02 | 1999-04-27 | Merck & Co., Inc. | Inhibitors of prenyl-protein transferase |
| JP4135318B2 (ja) | 1997-12-15 | 2008-08-20 | アステラス製薬株式会社 | 新規なピリミジン−５−カルボキサミド誘導体 |
| DE69918799D1 (de) | 1998-01-14 | 2004-08-26 | Uab Res Foundation Birmingham | Verfahren zur herstellung und screening von inhibitoren des bakteriellen nad synthetase enzyms, verbindungen daraus und methoden zur behandlung bakterieller und mikrobieller infektionen mit diesen inhibitoren |
| US6506766B1 (en) | 1998-02-13 | 2003-01-14 | Abbott Laboratories | Glucocortiocoid-selective antinflammatory agents |
| US6255303B1 (en) | 1998-03-14 | 2001-07-03 | Byk Gulden Lomberg Chemische Fabrik Gmbh | Phthalazinone PDE III/IV inhibitors |
| JP2002516305A (ja) | 1998-05-12 | 2002-06-04 | アメリカン・ホーム・プロダクツ・コーポレイション | インスリン抵抗性および高血糖症の治療に有用な２，３，５−置換ビフェニル |
| GB9811599D0 (en) | 1998-05-30 | 1998-07-29 | Glaxo Group Ltd | Nitric oxide synthase inhibitors |
| CA2362401A1 (en) | 1999-02-04 | 2000-08-10 | Paul Fleming | G-protein coupled heptahelical receptor binding compounds and methods of use thereof |
| EP1175422A2 (en) | 1999-05-04 | 2002-01-30 | Ligand Pharmaceuticals Incorporated | Tetracyclic progesterone receptor modulator compounds and methods |
| JP2002544258A (ja) | 1999-05-12 | 2002-12-24 | ニューロサーチ、アクティーゼルスカブ | イオンチャネル調節剤 |
| CA2376892A1 (en) | 1999-06-29 | 2001-01-04 | The Uab Research Foundation | Methods of treating fungal infections with inhibitors of nad synthetase enzyme |
| ES2165768B1 (es) | 1999-07-14 | 2003-04-01 | Almirall Prodesfarma Sa | Nuevos derivados de quinuclidina y composiciones farmaceuticas que los contienen. |
| CO5180649A1 (es) | 1999-09-01 | 2002-07-30 | Abbott Lab | Antagonistas de los receptores de los glucocorticoides para el tratamiento de la diabetes para el tratamiento de la diabetes |
| OA11558A (en) | 1999-12-08 | 2004-06-03 | Advanced Medicine Inc | Beta 2-adrenergic receptor agonists. |
| WO2001074331A1 (en) | 2000-04-04 | 2001-10-11 | Shionogi & Co., Ltd. | Oily compositions containing highly fat-soluble drugs |
| AU2001244610A1 (en) | 2000-04-05 | 2001-10-23 | Shionogi And Co., Ltd. | Oil-in-water microemulsions containing tricyclic compounds or preconcentrates thereof |
| ATE416184T1 (de) | 2000-08-05 | 2008-12-15 | Glaxo Group Ltd | 17.beta.-carbothioat 17.alpha.- arylkarbonyloxyloxy androstanderivate als anti- phlogistische medikamente |
| BR0114323A (pt) | 2000-09-29 | 2003-07-01 | Glaxo Group Ltd | Composto ou um seu sal ou solvato farmaceuticamente aceitável, composição farmacêutica, uso do composto ou de um seu sal ou solvato farmaceuticamente aceitável, método de tratamento ou profilaxia de doenças inflamatórias, e, processo para preparar o composto |
| GB0031179D0 (en) | 2000-12-21 | 2001-01-31 | Glaxo Group Ltd | Nitric oxide synthase inhibitors |
| US6484903B2 (en) | 2001-01-09 | 2002-11-26 | Riverwood International Corporation | Carton with an improved dispensing feature in combination with a unique handle |
| GB0103630D0 (en) | 2001-02-14 | 2001-03-28 | Glaxo Group Ltd | Chemical compounds |
| ES2288543T3 (es) | 2001-03-08 | 2008-01-16 | Glaxo Group Limited | Agonistas de beta-adrenorreceptores. |
| JP4143413B2 (ja) | 2001-03-22 | 2008-09-03 | グラクソ グループ リミテッド | β２−アドレナリン受容体アゴニストとしてのホルムアニリド誘導体 |
| WO2002088167A1 (en) | 2001-04-30 | 2002-11-07 | Glaxo Group Limited | Anti-inflammatory 17.beta.-carbothioate ester derivatives of androstane with a cyclic ester group in position 17.alpha |
| EP1395604B1 (en) | 2001-06-12 | 2008-06-25 | Glaxo Group Limited | Novel anti inflammatory 17.alpha.-heterocyclic-esters of 17.beta.-carbothioate androstane derivatives |
| EP1578898A2 (en) | 2001-07-13 | 2005-09-28 | Virtual Drug Development, Inc. | Nad synthetase inhibitors and uses thereof |
| PL393155A1 (pl) | 2001-09-14 | 2011-03-28 | Glaxo Group Limited | Pochodne fenetanoloaminy do leczenia chorób układu oddechowego |
| WO2003042160A1 (en) | 2001-11-13 | 2003-05-22 | Theravance, Inc. | Aryl aniline beta-2 adrenergic receptor agonists |
| WO2003050174A1 (en) | 2001-12-11 | 2003-06-19 | Rhodia Chimie | Catalytic pgm mixture for hydrosilylation |
| US20030187026A1 (en) | 2001-12-13 | 2003-10-02 | Qun Li | Kinase inhibitors |
| US20030158195A1 (en) | 2001-12-21 | 2003-08-21 | Cywin Charles L. | 1,6 naphthyridines useful as inhibitors of SYK kinase |
| DE60309829T2 (de) | 2002-01-14 | 2007-09-13 | Boehringer Ingelheim Pharmaceuticals, Inc., Ridgefield | Glucocorticoidmimetika, verfahren zu ihrer herstellung, diese enthaltende pharmazeutische formulierungen und ihre verwendungen |
| US6831093B2 (en) | 2002-01-22 | 2004-12-14 | The Regents Of The University Of California | Non-steroidal ligands for the glucocorticoid receptor, compositions and uses thereof |
| GB0204719D0 (en) | 2002-02-28 | 2002-04-17 | Glaxo Group Ltd | Medicinal compounds |
| KR101022977B1 (ko) | 2002-03-26 | 2011-03-18 | 베링거 인겔하임 파마슈티칼즈, 인코포레이티드 | 글루코코르티코이드 모사체, 이의 제조방법, 약제학적조성물 및 이의 용도 |
| JP2005521717A (ja) | 2002-03-26 | 2005-07-21 | ベーリンガー インゲルハイム ファーマシューティカルズ インコーポレイテッド | グルココルチコイドミメチックス、その製造方法、その医薬組成物、及び使用 |
| DE10215316C1 (de) | 2002-04-02 | 2003-12-18 | Schering Ag | Chinolin- und Isochinolin-Derivate, ein pharmazeutisches Mittel und ihre Verwendung als Entzündungshemmer |
| US7282591B2 (en) | 2002-04-11 | 2007-10-16 | Merck & Co., Inc. | 1h-benzo{f}indazol-5-yl derivatives as selective glucocorticoid receptor modulators |
| JP2005523920A (ja) | 2002-04-25 | 2005-08-11 | グラクソ グループ リミテッド | フェネタノールアミン誘導体 |
| US7186864B2 (en) | 2002-05-29 | 2007-03-06 | Boehringer Ingelheim Pharmaceuticals, Inc. | Glucocorticoid mimetics, methods of making them, pharmaceutical compositions, and uses thereof |
| US7074806B2 (en) | 2002-06-06 | 2006-07-11 | Boehringer Ingelheim Pharmaceuticals, Inc. | Glucocorticoid mimetics, methods of making them, pharmaceutical compositions, and uses thereof |
| EP1521733B1 (en) | 2002-07-08 | 2014-08-20 | Pfizer Products Inc. | Modulators of the glucocorticoid receptor |
| PL375442A1 (en) | 2002-07-18 | 2005-11-28 | Bristol-Myers Squibb Company | Modulators of the glucocorticoid receptor and method |
| GB0217225D0 (en) | 2002-07-25 | 2002-09-04 | Glaxo Group Ltd | Medicinal compounds |
| AU2003259747A1 (en) | 2002-08-21 | 2004-03-11 | Boehringer Ingelheim Pharmaceuticals, Inc. | Substituted hihydroquinolines as glucocorticoid mimetics, methods of making them, pharmaceutical compositions, and uses thereof |
| GB0220730D0 (en) | 2002-09-06 | 2002-10-16 | Glaxo Group Ltd | Medicinal compounds |
| WO2004024728A2 (en) | 2002-09-16 | 2004-03-25 | Glaxo Group Limited | Pyrazolo[3,4-b]pyridine compounds, and their use as phosphodiesterase inhibitors |
| GB0230045D0 (en) | 2002-12-23 | 2003-01-29 | Glaxo Group Ltd | Compounds |
| CA2499150A1 (en) | 2002-09-20 | 2004-04-01 | Merck & Co., Inc. | Octahydro-2-h-naphtho[1,2-f] indole-4-carboxamide derivatives as selective glucocorticoid receptor modulators |
| GB0224084D0 (en) | 2002-10-16 | 2002-11-27 | Glaxo Group Ltd | Novel compounds |
| EP1558753A2 (en) | 2002-10-16 | 2005-08-03 | Millennium Pharmaceuticals, Inc. | Spleen tyrosine kinase catalytic domain: crystal structure and binding pockets thereof |
| EP1554264B1 (en) | 2002-10-22 | 2007-08-08 | Glaxo Group Limited | Medicinal arylethanolamine compounds |
| BR0315720A (pt) | 2002-10-28 | 2005-09-06 | Glaxo Group Ltd | Composto, método para a profilaxia ou tratamento de uma condição clìnica em um mamìmefero, formulação farmacêutica, combinação, uso de um composto, processo para a preparação de um composto, e, intermediário |
| GB0225030D0 (en) | 2002-10-28 | 2002-12-04 | Glaxo Group Ltd | Medicinal compounds |
| GB0225535D0 (en) | 2002-11-01 | 2002-12-11 | Glaxo Group Ltd | Medicinal compounds |
| GB0225540D0 (en) | 2002-11-01 | 2002-12-11 | Glaxo Group Ltd | Medicinal compounds |
| EP2186516B1 (en) | 2002-12-20 | 2013-01-16 | Glaxo Group Limited | Novel benzazepine derivative |
| TWI328009B (en) | 2003-05-21 | 2010-08-01 | Glaxo Group Ltd | Quinoline derivatives as phosphodiesterase inhibitors |
| GB0316290D0 (en) | 2003-07-11 | 2003-08-13 | Glaxo Group Ltd | Novel compounds |
| CN101031539A (zh) * | 2003-08-14 | 2007-09-05 | 旭化成制药株式会社 | 取代的芳基链烷酸衍生物及其用途 |
| JP4641526B2 (ja) | 2003-11-03 | 2011-03-02 | グラクソ グループ リミテッド | 流体分配デバイス |
| JP2005170939A (ja) | 2003-11-20 | 2005-06-30 | Takeda Chem Ind Ltd | 糖尿病の予防・治療剤 |
| BRPI0508098A (pt) | 2004-02-27 | 2007-07-17 | Amgen Inc | compostos, composições farmacêuticas e métodos para uso no tratamento de distúrbios metabólicos |
| JP2007527918A (ja) | 2004-03-08 | 2007-10-04 | アムジェン インコーポレイテッド | Ｐｐａｒガンマ活性の治療的調節 |
| WO2006000398A1 (en) | 2004-06-28 | 2006-01-05 | Glaxo Group Limited | 2,3-benzoxazin derivatives as non-steroidal glucocorticoid receptor modulators |
| WO2006000401A1 (en) | 2004-06-28 | 2006-01-05 | Glaxo Group Limited | Substituted oxazines as glucocorticoid receptor modulators |
| GB0418045D0 (en) | 2004-08-12 | 2004-09-15 | Glaxo Group Ltd | Compounds |
| ES2367515T3 (es) | 2004-10-19 | 2011-11-04 | F. Hoffmann-La Roche Ag | Derivados de quinolina. |
| ATE517908T1 (de) | 2005-01-10 | 2011-08-15 | Glaxo Group Ltd | Androstan-17-alpha-carbonat-derivate zur verwendung bei der behandlung allergischer und entzündlicher zustände |
| US20090124588A1 (en) | 2005-01-10 | 2009-05-14 | Glaxo Group Limited | Androstane 17-Alpha-Carbonate for Use in the Treatment of Inflammatory and Allergic Conditions |
| AU2006210513C1 (en) | 2005-02-04 | 2012-10-25 | Senomyx, Inc. | Compounds comprising linked heteroaryl moieties and their use as novel umami flavor modifiers, tastants and taste enhancers for comestible compositions |
| US8093281B2 (en) | 2005-04-14 | 2012-01-10 | Glaxo Group Limited | Indazoles as glucocorticoid receptor ligands |
| GB0513297D0 (en) | 2005-06-29 | 2005-08-03 | Glaxo Group Ltd | Novel compounds |
| PE20070362A1 (es) | 2005-07-15 | 2007-04-23 | Glaxo Group Ltd | COMPUESTOS DERIVADOS DE INDAZOL-4-IL-2,4-PIRIMIDINDIAMINA COMO INHIBIDORES DE TIROSINA QUINASA (QUINASA Syk) |
| JP2007063225A (ja) * | 2005-09-01 | 2007-03-15 | Takeda Chem Ind Ltd | イミダゾピリジン化合物 |
| EP1924546A1 (en) | 2005-09-14 | 2008-05-28 | Amgen, Inc | Conformationally constrained 3- (4-hydroxy-phenyl) - substituted-propanoic acids useful for treating metabolic disorders |
| US20070225285A1 (en) | 2005-11-04 | 2007-09-27 | Amira Pharmaceuticals, Inc. | 5-lipoxygenase-activating protein (flap) inhibitors |
| US20070104620A1 (en) | 2005-11-07 | 2007-05-10 | Bilal Zuberi | Catalytic Exhaust Device |
| GB0522880D0 (en) | 2005-11-09 | 2005-12-21 | Glaxo Group Ltd | Novel compounds |
| EP2061760A1 (en) | 2006-09-07 | 2009-05-27 | Amgen, Inc | Benzo-fused compounds for use in treating metabolic disorders |
| WO2008046216A1 (en) | 2006-10-18 | 2008-04-24 | Methylgene, Inc. | Kinase inhibitors and uses thereof |
| HUE035868T2 (en) | 2006-11-15 | 2018-05-28 | Ym Biosciences Australia Pty | Inhibitors of kinase activity |
| WO2008079277A1 (en) | 2006-12-22 | 2008-07-03 | Millennium Pharmaceuticals, Inc. | Certain pyrazoline derivatives with kinase inhibitory activity |
| TW201006090A (en) | 2008-07-16 | 2010-02-01 | Chien-Chiang Chan | Applied structure of energy storage device |
| US8604049B2 (en) | 2008-08-05 | 2013-12-10 | Boehringer Ingelheim International Gmbh | 4-dimethylamino-phenyl-substituted naphthyridines, and use thereof as medicaments |
| WO2010015529A1 (en) | 2008-08-05 | 2010-02-11 | Nicox S.A. | New no releasing steroids derivatives |
| GB0910691D0 (en) | 2009-06-19 | 2009-08-05 | Glaxo Group Ltd | Novel compounds |
| AU2010314891A1 (en) | 2009-11-06 | 2012-06-07 | Vanderbilt University | Aryl and heteroaryl sulfones as MGLUR4 allosteric potentiators, compositions, and methods of treating neurological dysfunction |
-
2011
- 2011-03-11 GB GBGB1104153.0A patent/GB201104153D0/en not_active Ceased
-
2012
- 2012-03-08 BR BR112013022784A patent/BR112013022784A2/pt not_active Application Discontinuation
- 2012-03-08 UY UY0001033942A patent/UY33942A/es not_active Application Discontinuation
- 2012-03-08 NO NO15166109A patent/NO2937344T3/no unknown
- 2012-03-08 HR HRP20150752TT patent/HRP20150752T1/hr unknown
- 2012-03-08 ME MEP-2017-218A patent/ME02872B/me unknown
- 2012-03-08 EP EP12707342.7A patent/EP2683709B1/en active Active
- 2012-03-08 LT LTEP15166109.7T patent/LT2937344T/lt unknown
- 2012-03-08 SG SG2013065750A patent/SG193015A1/en unknown
- 2012-03-08 MX MX2013010373A patent/MX339123B/es active IP Right Grant
- 2012-03-08 KR KR1020137026876A patent/KR101564007B1/ko not_active Expired - Fee Related
- 2012-03-08 EA EA201391165A patent/EA022437B1/ru not_active IP Right Cessation
- 2012-03-08 ME MEP-2015-102A patent/ME02167B/me unknown
- 2012-03-08 ES ES15166109.7T patent/ES2641483T3/es active Active
- 2012-03-08 SM SM20170538T patent/SMT201700538T1/it unknown
- 2012-03-08 AR ARP120100750A patent/AR085711A1/es unknown
- 2012-03-08 CA CA2828518A patent/CA2828518C/en not_active Expired - Fee Related
- 2012-03-08 RS RS20150449A patent/RS54120B1/sr unknown
- 2012-03-08 PE PE2013002037A patent/PE20140998A1/es active IP Right Grant
- 2012-03-08 WO PCT/EP2012/053948 patent/WO2012123311A1/en not_active Ceased
- 2012-03-08 AU AU2012228439A patent/AU2012228439C1/en not_active Ceased
- 2012-03-08 PT PT151661097T patent/PT2937344T/pt unknown
- 2012-03-08 MY MYPI2013701607A patent/MY169314A/en unknown
- 2012-03-08 US US13/414,873 patent/US8993560B2/en not_active Expired - Fee Related
- 2012-03-08 HU HUE12707342A patent/HUE026541T2/en unknown
- 2012-03-08 SI SI201230253T patent/SI2683709T1/sl unknown
- 2012-03-08 SI SI201231072T patent/SI2937344T1/sl unknown
- 2012-03-08 EP EP15166109.7A patent/EP2937344B1/en active Active
- 2012-03-08 DK DK12707342.7T patent/DK2683709T3/en active
- 2012-03-08 CN CN201280022632.7A patent/CN103502239B/zh not_active Expired - Fee Related
- 2012-03-08 US US14/004,388 patent/US20140005177A1/en not_active Abandoned
- 2012-03-08 HU HUE15166109A patent/HUE035443T2/en unknown
- 2012-03-08 RS RS20170962A patent/RS56719B1/sr unknown
- 2012-03-08 JP JP2013557086A patent/JP5902206B2/ja not_active Expired - Fee Related
- 2012-03-08 MA MA36313A patent/MA35030B1/fr unknown
- 2012-03-08 DK DK15166109.7T patent/DK2937344T3/en active
- 2012-03-08 PT PT127073427T patent/PT2683709E/pt unknown
- 2012-03-08 PH PH1/2013/501854A patent/PH12013501854A1/en unknown
- 2012-03-08 PL PL15166109T patent/PL2937344T3/pl unknown
- 2012-03-08 JO JOP/2012/0050A patent/JO3072B1/ar active
- 2012-03-08 PL PL12707342T patent/PL2683709T3/pl unknown
- 2012-03-08 ES ES12707342.7T patent/ES2541530T3/es active Active
- 2012-03-08 TW TW101107813A patent/TWI527806B/zh not_active IP Right Cessation
- 2012-08-03 UA UAA201310451A patent/UA109807C2/uk unknown
-
2013
- 2013-08-08 IL IL227873A patent/IL227873A/en active IP Right Grant
- 2013-08-20 CO CO13197322A patent/CO6791612A2/es active IP Right Grant
- 2013-08-30 ZA ZA2013/06554A patent/ZA201306554B/en unknown
- 2013-09-10 CL CL2013002602A patent/CL2013002602A1/es unknown
- 2013-09-11 CR CR20130459A patent/CR20130459A/es unknown
- 2013-09-11 DO DO2013000207A patent/DOP2013000207A/es unknown
-
2015
- 2015-02-19 US US14/625,804 patent/US9447074B2/en not_active Expired - Fee Related
- 2015-07-24 CY CY20151100654T patent/CY1116569T1/el unknown
- 2015-08-05 SM SM201500188T patent/SMT201500188B/xx unknown
-
2016
- 2016-08-19 US US15/241,160 patent/US20160355505A1/en not_active Abandoned
-
2017
- 2017-10-27 HR HRP20171647TT patent/HRP20171647T1/hr unknown
- 2017-11-08 CY CY20171101175T patent/CY1119581T1/el unknown
Also Published As
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| AR085711A1 (es) | Compuesto de heteroaril oximetilen arilo sustituido, composicion farmaceutica y combinacion que lo comprenden y su uso para la fabricacion de un medicamento para el tratamiento de una enfermedad autoinmune, cancer, una enfermedad inflamatoria y/o un trastorno alergico y una enfermedad asociada con la activacion inapropiada de las celulas cebadas | |
| AR089781A1 (es) | Fluorometil-5,6-dihidro-4h-[1,3]oxazinas | |
| NI201700020A (es) | Compuestos de aminopirimidinilo como inhibidores de jak | |
| CR20130588A (es) | Halogenoalquil-1,3-oxazinas como inhibidores de la bace1 y/o bace 2 | |
| ECSP13013024A (es) | 1,3-oxazinas como inhibidores de bace1 y/o bace2 | |
| AR100006A1 (es) | Derivados de tubulisina | |
| CU20150014A7 (es) | Análogos de piridazina 1,4-disustituida y métodos para el tratamiento de condiciones relacionadas con la deficiencia de smn | |
| CL2012003745A1 (es) | Compuestos derivados de aminopirazoloquinazolinas, como inhibidores frente a la actividad fosforilante del receptor igf-1 localizado en membranas celulares; preparacion farmaceutica que los contiene; y su uso en el tratamiento y/o prevencion de cancer, infecciones, enfermedades inflamatorias y autoinmunitarias. | |
| EA201891049A1 (ru) | Изоиндолиновые, азаизоиндолиновые, дигидроинденоновые и дигидроазаинденоновые ингибиторы mnk1 и mnk2 | |
| CR20150628A (es) | Derivados de la pirazolopirrolidina y su uso en el tratamiento de enfermedades | |
| EA202090291A2 (ru) | Производные бипиразола в качестве ингибиторов jak | |
| MX383686B (es) | Derivados de piridazina 1,4-disustituida, y su uso para el tratamiento de afecciones relacionadas con la deficiencia de smn. | |
| AR095034A1 (es) | El uso de los agonistas del receptor 2 del péptido formilo para el tratamiento de las enfermedades inflamatorias oculares | |
| AR106053A1 (es) | Compuestos imidazo[4,5-c]quinolin-2-ona y su uso para el tratamiento del cáncer | |
| EA201591727A1 (ru) | Соединения биариламида в качестве ингибиторов киназы | |
| EA201690247A1 (ru) | Аминометилбиарильные производные-ингибиторы фактора d комплемента и их применения | |
| EA202090860A1 (ru) | Аналоги тиадиазола и способы лечения состояний, связанных с дефицитом smn | |
| ECSP13012596A (es) | Proceso de elaboración para derivados de pirimidina | |
| EA202190167A1 (ru) | Замещенные фенилоксазолидиноны для антимикробной терапии | |
| UY35211A (es) | Compuestos tricíclicos | |
| DOP2014000114A (es) | Nuevos 2hindazoles como antagonistas del receptor ep2 | |
| MX373079B (es) | Uso de antagonistas del receptor de ep4 en el tratamiento de enfermedad de cartílago. | |
| CU24434B1 (es) | Compuestos derivados de n-(1,5-dimetil-3-oxo-2,3-dihidro-1h-pirazol-4-il)-4-metil-5-isoxazol-3-carboxamida activos como inhibidores selectivos de smurf-1 | |
| MX2017012926A (es) | Inhibidores y sus usos. | |
| UY35209A (es) | Compuestos tricíclicos |
Legal Events
| Date | Code | Title | Description |
|---|---|---|---|
| FB | Suspension of granting procedure |